Brokers Offer Predictions for MOLN FY2025 Earnings

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) – Analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for shares of Molecular Partners in a note issued to investors on Tuesday, January 27th. HC Wainwright analyst R. Burns expects that the company will post earnings of ($2.10) per share for the year. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.93) per share. HC Wainwright also issued estimates for Molecular Partners’ Q4 2025 earnings at ($0.40) EPS.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. lowered their price target on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a report on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Molecular Partners currently has an average rating of “Hold” and a consensus price target of $9.58.

Molecular Partners Stock Up 3.7%

Shares of Molecular Partners stock opened at $4.15 on Thursday. Molecular Partners has a twelve month low of $3.36 and a twelve month high of $5.35. The company’s 50 day moving average is $4.23 and its 200 day moving average is $3.94. The company has a market cap of $167.42 million, a price-to-earnings ratio of -2.16 and a beta of 1.07.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings results on Thursday, October 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.05.

Key Molecular Partners News

Here are the key news stories impacting Molecular Partners this week:

• Positive Sentiment: HC Wainwright initiated coverage with a “Buy”/”Strong‑Buy” stance and a $13.00 price target, implying roughly a 213.6% upside from the current price — a clear near‑term catalyst that can attract buyers and boost sentiment. The Fly
• Positive Sentiment: HC Wainwright’s model calls for narrowing year‑over‑year losses (FY2026 EPS -$1.70; FY2027 EPS -$1.64) versus the street consensus (~‑$1.93), suggesting the firm sees improving operating leverage or program milestones that could justify multiple expansion if progress is confirmed. Benzinga
• Neutral Sentiment: HC Wainwright published detailed quarterly EPS estimates for 2026–2027 (quarterly EPS ranges ~‑$0.39 to ‑$0.45), which provide a roadmap investors can use to track operational progress against the analyst’s thesis but are forecasts, not confirmed results. MarketBeat
• Negative Sentiment: Despite the bullish initiation, Molecular Partners remains unprofitable by consensus and HC Wainwright estimates; sustained product/clinical progress and capital strategy updates will be needed to support the lofty $13 target — absent clear execution, valuation upside could reverse. MarketBeat

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.